Literature DB >> 28739771

Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.

Yongping Yang1, Naihong Sun2, Ping Sun3, Liangming Zhang3.   

Abstract

AIM: This study was designed to evaluate the clinical characteristics and prognosis of elderly small cell lung cancer (SCLC) patients complicated with hyponatremia, thus providing increased attention for appropriate intervention and improving outcomes in symptomatic subjects. PATIENTS AND METHODS: The clinical data of 320 patients with SCLC in the Yuhuangding Hospital from March 1st, 2006, to March 1st, 2012, were studied retrospectively. The prognosis and possible association with hyponatremia was investigated.
RESULTS: The incidence rate of hyponatremia in SCLC was 46.56% (149/320). The mean survival time was 1.10±0.42 years in patients with normal values and 0.83±0.35 years in patients with subnormal serum sodium. In the hyponatremia group, the mean survival time of corrected hyponatremia patients was 0.91±0.42 years, which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years (t=2.75, p<0.05) after symptomatic treatment. The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients younger than 60 years old. Hyponatremia at 1- and 3-year follow-up was associated with worse survival rates (p<0.05).
CONCLUSION: The severity of hyponatremia has unfavorable prognostic impacts. Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival, especially in the uncorrected group. It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Small cell lung cancer; elderly patients; hyponatremia; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28739771     DOI: 10.21873/anticanres.11872

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Small-cell lung cancer with Mallory-Weiss syndrome as the prominent manifestation.

Authors:  Fengzhu Guo; Jiantao Wang; Kuncheng Liu; Zhen Zeng; Feng Luo
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

2.  Neither the presence nor the severity of hyponatremia affected the outcome of the patients with small cell lung cancer.

Authors:  Faruk Tas; Akin Ozturk; Kayhan Erturk
Journal:  Ir J Med Sci       Date:  2022-10-24       Impact factor: 2.089

3.  Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study.

Authors:  Min-Seok Seo; In Cheol Hwang; Jaehun Jung; Hwanhee Lee; Jae Hee Choi; Jae-Yong Shim
Journal:  BMC Palliat Care       Date:  2020-07-01       Impact factor: 3.234

4.  A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.

Authors:  Alvaro H Ingles Garces; Joo Ern Ang; Malaka Ameratunga; Maxime Chénard-Poirier; David Dolling; Nikolaos Diamantis; Satyanarayana Seeramreddi; Raghav Sundar; Johann de Bono; Juanita Lopez; Udai Banerji
Journal:  Eur J Cancer       Date:  2018-10-10       Impact factor: 9.162

Review 5.  A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.

Authors:  Ranpu Wu; Chuling Li; Zimu Wang; Hang Fan; Yong Song; Hongbing Liu
Journal:  Transl Lung Cancer Res       Date:  2020-12

6.  Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.

Authors:  Hong-Tao Jiang; Wei Li; Biao Zhang; Qiang Gong; Hai-Ling Qie
Journal:  Int J Gen Med       Date:  2021-11-02

7.  Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.

Authors:  Li-Ling Huang; Xing-Sheng Hu; Yan Wang; Jun-Ling Li; Hong-Yu Wang; Peng Liu; Jian-Ping Xu; Xiao-Hui He; Xue-Zhi Hao; Pei-Di Jiang; Yu-Tao Liu; Jian Luo; Sheng-Yu Zhou; Jin-Wan Wang; Jian-Liang Yang; Yan Qin; Peng Yuan; Lin Lin; Yuan-Kai Shi
Journal:  Thorac Cancer       Date:  2021-05-09       Impact factor: 3.500

8.  Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions.

Authors:  Peng-Fei Song; Ning Xu; Qin Li
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

9.  Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.

Authors:  Eszter Bartalis; Marin Gergics; Benedek Tinusz; Mária Földi; Szabolcs Kiss; Dávid Németh; Margit Solymár; Zsolt Szakács; Péter Hegyi; Emese Mezösi; László Bajnok
Journal:  Front Med (Lausanne)       Date:  2021-12-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.